Jacobs Levy Equity Management’s Adicet Bio ACET Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-20,850	Closed	-$457K	–	965
2023 Q3	$457K	Buy	20,850 +590	+3%	+$20.8K	﹤0.01%	820
2023 Q2	$788K	Buy	20,260 +2,962	+17%	+$261K	﹤0.01%	742
2023 Q1	$1.59M	Buy	17,298 +12,962	+299%	+$1.63M	0.01%	614
2022 Q4	$620K	Buy	+4,336	New	+$1.08M	﹤0.01%	752
2022 Q1	–	Sell	-1,719	Closed	-$481K	–	993
2021 Q4	$481K	Hold	1,719	–	–	﹤0.01%	839
2021 Q3	$216K	Hold	1,719	–	–	﹤0.01%	980
2021 Q2	$283K	Hold	1,719	–	–	﹤0.01%	939
2021 Q1	$360K	Hold	1,719	–	–	﹤0.01%	908
2020 Q4	$386K	Hold	1,719	–	–	﹤0.01%	883
2020 Q3	$327K	Buy	+1,719	New	+$435K	﹤0.01%	876

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's ACET Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Adicet Bio (ACET) in Q4 2023, closing a stake of 20,850 shares — an estimated $457K sold.

Jacobs Levy Equity Management first reported a position in ACET in Q3 2020 and held it in 10 quarters. The position peaked at $1.59M in Q1 2023. 76 funds tracked by Wall St. Rank hold ACET as of Q4 2023.

Jacobs Levy Equity Management reported no remaining Adicet Bio position as of Q4 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 20,850 Adicet Bio shares in Q4 2023, an estimated $457K.
Jacobs Levy Equity Management first reported a position in Adicet Bio in Q3 2020 and held it in 10 quarters.
Jacobs Levy Equity Management's Adicet Bio position peaked at $1.59M in Q1 2023.
76 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.